• Numab

  Led · Series B · Mar 2020

  Numab Therapeutics is a clinical-stage biopharmaceutical company based in the Zurich area/Waedenswil, Switzerland, focused on next-generation multispecific antibody-based immunotherapies for oncology and inflammation. The company uses proprietary MATCHTM (and Lambda-capTM) technologies to design multi-specific drug candidates with versatility and developability in mind. Its lead product, NM21-1480, is designed to target 4-1BB, PD-L1 and human serum albumin simultaneously, aiming to combine PD-L1 blockade with tumor-localized 4-1BB co-stimulation. Numab positions NM21-1480 as having best-in-class potential and intends to expand its clinical development into multiple cancer indications. The company recently completed an oversubscribed CHF 100 million Series C financing to accelerate and expand clinical development and advance its pipeline into clinical trials. Leadership includes Founder and CEO David Urech, Ph.D., and the financing brought new board additions from investors. Numab Therapeutics develops multispecific antibody-based therapeutics using its MATCH plug-and-play platform, which supports molecules with up to six binding specificities. Its lead candidate, ND021, is a PD-L1x4-1BBxHSA trispecific designed to simultaneously target PD-L1 and 4-1BB with a half-life extending HSA-binding motif. The company has partnered with firms including 3SBio, Eisai and Ono Pharmaceutical to advance its multispecific approach. Numab plans to start a clinical trial of ND021 this year and will allocate part of its recent financing to that trial. It also intends to expand its pipeline and advance other assets toward the clinic, including a preclinical anti-TNF antibody fragment for inflammatory bowel disease and several undisclosed multispecifics for chronic inflammation and immuno-oncology. The firm positions ND021 as potentially delivering existing immuno-oncology efficacy with a cleaner toxicity profile versus competing PD-L1/4-1BB programs.

No current team members are available.